Application of hematoporphyrin derivative combined with chemical drug in breast cancer treatment

Abstract

The invention belongs to the field of medicine and pharmacology for increasing sensitivity of chemotherapeutic drugs, and particularly relates to application of a hematoporphyrin-verapamil fragment hematoporphyrin derivative A2 in tolerance reversing and sensitization of breast cancer chemotherapeutic drugs. The hematoporphyrin derivative A2 has different degrees of sensitization of the chemotherapeutic drugs for inhibiting breast cancer cell proliferation, which indicates that the hematoporphyrin derivative A2 can be developed into a sensitizer or a reverse drug-resistant agent of the chemotherapeutic drugs and used for treating breast cancer patients.

Description

Technical field[0001]The invention belongs to the use of a pharmaceutically acceptable drug sensitivity to increase chemotherapeutic drugs, and more particularly to the use of hematoporphyrin 骈 骈 拉帕米 片 fragment hematoporphyrin derivative A2 in tolerance and sensitization of breast cancer inversion.[0002]technical background[0003]Chemotherapy is one of the most effective methods in current breast cancer. Since the introduction of chemotherapy in the mid-1990s, the incidence and mortality caused by breast cancer have been greatly reduced, and the life of patients with breast cancer is extended.[1]. However, the development of drug resistance ultimately became a huge challenge for successful chemotherapy of breast cancer. It is estimated that a large amount of breast cancer patients (up to 50%) have no reaction to the current chemotherapy solution.[2]. Drug resistance to a single anti-tumor drug tends to trigger a multi-effect drug resistance of multiple structural and functionally ind...

AI Technical Summary

Problems solved by technology

However, due to the low polarity of hematoporphyrin, it cannot be directly administered intravenously, which greatly limits its clinical application.

Images